Neurocrine Biosciences Inc
NBIX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000914475
In the last 90 days, Neurocrine Biosciences Inc insiders filed 0 open-market purchases and 4 sales; 786 institutions reported holding it in 13F filings for Q2 2026, worth $17.0B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $17.1B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $3.16M in total
- 4
- 13F holdersQ2 2026, +89 vs. previous quarter
- 786
- 13F valueReported value at the end of Q2 2026
- $17.0B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $2.86B
- +21.4% year over year
- Net income, FY2025
- $478.6M
- +40.2% year over year
- Free cash flow, FY2025
- $748.7M
- +34.4% year over year
- Revenue, Q3 FY2026
- $1.12B
- +41.2% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 6.45M
- Shares sold short
- Change
- +594.4K
- +10.2% vs. previous
- Days to cover
- 4.54
- At average daily volume
Superinvestors holding NBIX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding NBIX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Neurocrine Biosciences Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 3, 2026 (view filing)6:52 PM ET | Oct 30-Nov 3 | 4 days | Morrow George JDirector | SSale | −15.0K | $155.73 | −$2.34M | −59.1%10.4K after | 12 lots10b5-1 |
| Sep 15, 2026 (view filing)5:03 PM ET | Sep 14 | 1 day | Boyer David W.Chief Corp. Affairs Officer | SSale | −826 | $157.45 | −$130.1K | −8.7%8.72K after | 10b5-1 |
| Sep 15, 2026 (view filing)5:02 PM ET | Sep 14 | 1 day | Abernethy MattChief Financial Officer | SSale | −2.31K | $157.20 | −$363.3K | −5.1%42.8K after | 10b5-1 |
| Sep 10, 2026 (view filing)8:29 PM ET | Sep 9 | 1 day | Benevich EricChief Commercial Officer | SSale | −2.15K | $154.61 | −$333.0K | −3.2%64.4K after | 10b5-1 |
| Jul 30, 2026 (view filing)5:29 PM ET | Jul 28 | 2 days | Norwalk Leslie VDirector | SSale | −1.25K | $182.01 | −$227.5K | −44.0%1.59K after | 10b5-1 |
| Jul 13, 2026 (view filing)4:27 PM ET | Jul 10 | 3 days | Delaet IngridChief Regulatory Officer | SSale | −4.37K | $181.02 | −$790.5K | −21.2%16.2K after | 10b5-1 |
| Jul 13, 2026 (view filing)4:27 PM ET | Jul 9 | 4 days | Lippoldt DarinChief Legal Officer | SSale | −10.0K | $179.60 | −$1.80M | −15.4%54.7K after | 10b5-1 |
| Jul 9, 2026 (view filing)6:41 PM ET | Jul 7-9 | 2 days | Delaet IngridChief Regulatory Officer | SSale | −14.6K | $178.65 | −$2.60M | −47.3%16.2K after | 3 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26-29 | 4 days | Lippoldt DarinChief Legal Officer | SSale | −10.0K | $170.15 | −$1.70M | −15.4%54.7K after | 3 lots10b5-1 |
| Jun 9, 2026 (view filing) | Jun 5 | 4 days | Sherwin Stephen ADirector | SSale | −25.0K | $165.32 | −$4.13M | −61.2%15.9K after | 5 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 786 holdersThe largest institutional positions in Neurocrine Biosciences Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,711,607 | $2.31B | 0.03% | +326,000+2.4% | Added |
| JPMorgan Chase & Co | 6,398,674 | $1.09B | 0.06% | +956,607+17.6% | Added |
| Dodge & Cox | 5,584,707 | $941.2M | 0.49% | +123,670+2.3% | Added |
| Vanguard Portfolio Management LLC | 4,974,083 | $838.3M | 0.04% | +247,739+5.2% | Added |
| Vanguard Capital Management LLC | 4,545,339 | $766.0M | 0.02% | +33,435+0.7% | Added |
| State Street Corp | 4,385,598 | $739.1M | 0.02% | +31,072+0.7% | Added |
| AQR Capital Management LLC | 3,818,037 | $643.5M | 0.22% | −1,120,930−22.7% | Reduced |
| Renaissance Technologies LLC | 2,335,897 | $393.7M | 0.54% | −83,000−3.4% | Reduced |
| Geode Capital Management, LLC | 2,138,777 | $359.6M | 0.02% | +2,105+0.1% | Added |
| Two Sigma Investments, LP | 2,076,260 | $349.9M | 0.26% | −984,310−32.2% | Reduced |
Holders of 5% or more of NBIX
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Neurocrine Biosciences Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 12.10%12.1M shares | – | Apr 28, 20251 filing | Apr 28, 2025 | SEC |
| Dodge & Cox | 13G | 5.60%5.53M shares | New | May 14, 20251 filing | May 14, 2025 | SEC |
| Vanguard Capital Management LLC | 13G | 5.23%5.26M shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
| JPMorgan Chase & Co | 13G/A | 5.20%5.30M shares | −1.10 ppfrom 6.30% | Jan 21, 20263 filings | Oct 15, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.00%5.08M shares | New | Oct 30, 20261 filing | Oct 30, 2026 | SEC |
Politician trades
All politician trades in NBIX2 members of Congress reported 4 trades in Neurocrine Biosciences Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Aug 13, 2025 |  Lisa C. McClain House · MI | Sell (partial) | $1K-$15K |
| Aug 13, 2025 | Lisa C. McClain House · MI | Buy | $1K-$15K |
| Jan 11, 2021 |  Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Aug 19, 2020 | Gilbert Ray Cisneros, Jr. House · CA | Sell (partial) | $1K-$15K |
House · MI · Aug 13, 2025
Sell (partial)$1K-$15K
House · MI · Aug 13, 2025
Buy$1K-$15K
House · CA · Jan 11, 2021
Buy$1K-$15K
House · CA · Aug 19, 2020
Sell (partial)$1K-$15K